Thanks for your reply. I appreciate your response and each of your points are valid. I have mentioned that I have a family member with DMD and have seen what this disease does to the body. It's ruthless. It's a tough, tough disease to combat. Given how bad this disease is, I would be very surprised if we don't get AA. Making this drug available to boys with exon 51 problems is the right thing to do. There is no downside.
My point is that volatility is here to stay until things get resolved. There are still many risks and people will bet against it. The stock, SRPT, is simply a call option on eteplirsen. There is no underlying value.
I hope it all works out. It's time for the DMD community to have some hope placed on a real drug.